The FDA has approved Exdensur for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients aged 12 and older.

Sen. Ron Johnson said in a letter Monday that he will continue to push for documents about deaths following the COVID-19 ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...

Drug trials offer people with cancer hope and free medicine, but they also create incentives for doctors in private clinics ...

Exdensur is the first and only ultra-long-acting biologic for patients with severe asthma with an eosinophilic phenotype.

Pfizer, which makes the shot, is fighting a lawsuit from more than 1,000 women who claim the company knew about the risk of meningiomas but failed to warn patients. Meanwhile, former Vice President ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

Although development of a jab for the H5N1 strain of avian flu is well under way, other strains are receiving less attention ...

FDA approves GSK's Exdensur for severe eosinophilic asthma, backed by Phase 3 data showing up to 58% fewer asthma attacks ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | On ...